文献速递神经眼科

视神经炎的视力预后及其相关因素与胶质自身抗体状态的关系

Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies.
PubMed 文献 · Am J Ophthalmol · 2022-01-23

这项纵向观察性队列研究纳入529例视神经炎患者共1022次发作,按血清胶质自身抗体状态分组,评估视力预后及相关因素。AQP4-IgG阳性组严重视力丧失比例高于双血清阴性组和MOG-IgG阳性组,而MOG-IgG阳性组良好视力恢复比例最高。多变量分析显示AQP4-IgG阳性、男性、起病年龄>45岁、最低视力≤20/200及复发次数多与严重视力丧失相关。

要点

  • AQP4-IgG阳性组严重视力丧失比例为42.9%,高于双血清阴性组的31.2%和MOG-IgG阳性组的5.9%(P < .001)。
  • MOG-IgG阳性组良好视力恢复比例为90.2%,高于双血清阴性组的50.9%和AQP4-IgG阳性组的42.9%(P < .001)。
  • AQP4-IgG阳性与严重视力丧失相关(OR 1.66;95% CI 1.14, 2.43;P = .008),MOG-IgG阳性与良好视力结局相关(OR 8.13;95% CI 4.82, 14.2;P < .001)。

核心结论

  • 严重视力丧失在AQP4-IgG组、MOG-IgG组和双血清阴性组的比例分别为42.9%、5.9%和31.2%,与AQP4-IgG阳性、男性、起病年龄较大、最低视力较差及复发次数较多相关。

研究设计与样本

  • 纵向观察性队列研究,连续纳入并纵向随访视神经炎且检测血清胶质自身抗体的患者,最短随访3个月,排除多发性硬化及双血清阴性结果者。
  • 共纳入529例患者(AQP4-IgG阳性291例、MOG-IgG阳性112例、双血清阴性126例),共1022次视神经炎发作(AQP4-IgG阳性550次、MOG-IgG阳性254次、双血清阴性218次)。

主要发现

  • 严重视力丧失(随访结束时最佳矫正视力BCVA≤20/200)比例在AQP4-IgG组为236/550(42.9%),高于双血清阴性组的68/218(31.2%)和MOG-IgG组的15/254(5.9%)(P < .001)。
  • 良好视力恢复(BCVA≥20/40)比例在MOG-IgG组为229/254(90.2%),高于双血清阴性组的111/218(50.9%)和AQP4-IgG组的236/550(42.9%)(P < .001)。
  • 多变量logistic分析中,严重视力丧失比例较高与AQP4-IgG阳性(OR 1.66;95% CI 1.14, 2.43;P = .008)、男性(OR 1.97;95% CI 1.33, 2.93;P < .001)、起病年龄>45岁(OR 1.93;95% CI 1.35, 2.77;P < .001)、最低视力≤20/200(OR 14.11;95% CI 6.54, 36.93;P < .001)及复发次数较多(OR 1.35;95% CI 1.14, 1.61;P = .001)相关。
  • 良好视力结局比例较高与MOG-IgG阳性(OR 8.13;95% CI 4.82, 14.2;P < .001)、起病年龄<18岁(OR 1.78;95% CI 1.18, 2.71;P = .006)、最低视力≥20/40(OR 4.03;95% CI 1.45, 14.37;P = .015)及复发次数较少(OR 0.60;95% CI 0.50, 0.72;P < .001)相关。

关键数值与推荐

  • 严重视力丧失定义为随访结束时BCVA≤20/200。
  • 良好视力恢复定义为BCVA≥20/40。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the visual prognosis of optic neuritis (ON) in dependence of the glial autoimmune antibody status and associated factors. DESIGN: Longitudinal observational cohort study. METHODS: Patients with ON and measurements of serum concentrations of glial autoantibodies were consecutively and longitudinally examined with a minimal follow-up of 3 months. Patients with multiple sclerosis and double seronegative results were excluded. RESULTS: The study included 529 patients (aquaporin-4 immunoglobulin [AQP4-IgG] seropositive, n = 291; myelin oligodendrocyte glycoprotein immunoglobulin [MOG-IgG] seropositive, n = 112; double-seronegative, n = 126) with 1022 ON episodes (AQP4-IgG seropositive, n = 550; MOG-IgG seropositive, n=254; double-seronegative, n = 218). Prevalence of severe vision loss (best-corrected visual acuity [BCVA] ≤20/200 at the end of follow-up) was higher (P < .001) in the AQP4-IgG group (236/550; 42.9%) than in the seronegative group (68/218; 31.2%) and in the MOG-IgG group (15/254; 5.9%). Prevalence of good vision recovery (BCVA≥20/40) was higher (P < .001) in the MOG-IgG group (229/254; 90.2%) than in the seronegative group (111/218; 50.9%) and in the AQP4-IgG group (236/550; 42.9%). In multivariable logistic analysis, higher prevalence of severe vision loss was associated with AQP4-IgG seropositivity (odds ratio [OR] 1.66; 95% CI 1.14, 2.43; P = .008), male sex (OR 1.97, 95% CI 1.33, 2.93; P < .001), age at ON onset >45 years (OR 1.93, 95% CI 1.35, 2.77; P < .001), nadir vision ≤20/200 (OR 14.11, 95% CI 6.54, 36.93; P < .001), and higher number of recurrences (OR 1.35, 95% CI 1.14, 1.61; P = .001). Higher prevalence of good vision outcome was associated with MOG-IgG seropositivity (OR 8.13, 95% CI 4.82, 14.2; P < .001), age at ON onset <18 years (OR 1.78, 95% CI 1.18, 2.71; P = .006), nadir visual acuity ≥20/40 (OR 4.03; 95% CI 1.45, 14.37; P = .015), and lower number of recurrences (OR 0.60; 95% CI 0.50, 0.72; P < .001). CONCLUSION: Severe vision loss (prevalence in the AQP4-IgG group, MOG-IgG group, and seronegative group: 42.9%, 5.9%, and 31.2%, respectively) was associated with AQP4-IgG seropositivity, male gender, older age at onset, worse nadir vision, and higher number of recurrences.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Yang M, Wu Y, Song H, et al. Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies. Am J Ophthalmol. 2022. PMID: 35081416. doi:10.1016/j.ajo.2022.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。